These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25109950)

  • 1. Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.
    Leroy C; Amante RJ; Bentires-Alj M
    Biochem Soc Trans; 2014 Aug; 42(4):733-41. PubMed ID: 25109950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
    Baselga J
    Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
    Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
    Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
    O'Regan R; Hawk NN
    Expert Opin Ther Targets; 2011 Jul; 15(7):859-72. PubMed ID: 21476875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K-Akt pathway: its functions and alterations in human cancer.
    Osaki M; Oshimura M; Ito H
    Apoptosis; 2004 Nov; 9(6):667-76. PubMed ID: 15505410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting phosphoinositide 3-kinase signalling in lung cancer.
    Wojtalla A; Arcaro A
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):278-90. PubMed ID: 21316260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
    Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer.
    Naumann RW
    Gynecol Oncol; 2011 Nov; 123(2):411-20. PubMed ID: 21903247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of PI3K inhibitors in advanced breast cancer.
    Verret B; Cortes J; Bachelot T; Andre F; Arnedos M
    Ann Oncol; 2019 Dec; 30 Suppl 10():x12-x20. PubMed ID: 31928690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
    Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
    Zhang J; Roberts TM; Shivdasani RA
    Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the PI3K pathway: hope we can believe in?
    van der Heijden MS; Bernards R
    Clin Cancer Res; 2010 Jun; 16(12):3094-9. PubMed ID: 20400520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging strategies for targeting PI3K in gynecologic cancer.
    Bregar AJ; Growdon WB
    Gynecol Oncol; 2016 Feb; 140(2):333-44. PubMed ID: 26432040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K inhibition to overcome endocrine resistance in breast cancer.
    Keegan NM; Gleeson JP; Hennessy BT; Morris PG
    Expert Opin Investig Drugs; 2018 Jan; 27(1):1-15. PubMed ID: 29252036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Vasan N; Toska E; Scaltriti M
    Ann Oncol; 2019 Dec; 30(Suppl_10):x3-x11. PubMed ID: 31859348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.